Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-02-06

Clinical Trial Update: Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol [Phase 3]

View source ↗

Summary

A Phase 3 study protocol evaluating imiquimod for residual or recurrent cervical intraepithelial neoplasia lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imiquimod (imiquimod)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Cervical Intraepithelial Neoplasia | Phase 3 | Status: UNKNOWN